The TRINITY Study: distribution of systolic blood pressure reductions | Zendy

Danny Sugimoto | Zendy; Steven G. Chrysant | Zendy; Melino | Zendy; Lee | Zendy; Fernández | Zendy; Heyrman | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The TRINITY Study: distribution of systolic blood pressure reductions

Author(s) -

Danny Sugimoto,

Steven G. Chrysant,

Melino,

Lee,

Fernández,

Heyrman

Publication year - 2013

Publication title -

integrated blood pressure control

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.652

H-Index - 20

ISSN - 1178-7104

DOI - 10.2147/ibpc.s45450

Subject(s) - amlodipine , hydrochlorothiazide , blood pressure , medicine , olmesartan , combination therapy , diastole , urology

Elevated systolic blood pressure is more difficult to control than elevated diastolic blood pressure. The objective of this prespecified analysis of the Triple Therapy with Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide in Hypertensive Patients Study (TRINITY) was to compare the efficacy of olmesartan medoxomil (OM) 40 mg, amlodipine besylate (AML) 10 mg, and hydrochlorothiazide (HCTZ) 25 mg triple-combination treatment with the component dual-combination treatments in reducing elevated seated systolic blood pressure (SeSBP).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research